Philip has more than 20 years' experience writing about companies, general finance and investing matters for a variety of publications. His career has involved spells at the Investors Chronicle, where he was small companies and companies editor, Investors Week and most recently as editor of online financial news wire Sharecast. He has also contributed to a wide range of financial-focused publications on a freelance basis.
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
The award recognised the innovation and scientific credibility behind SlimBiome, said chief executive Stephen O'Hara
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Slimbiome has been short-listed for best functional ingredient for health and wellbeing in the upcoming Food Matters Live
AstraZeneca intends to file for the trial data to be included to widen the marketing label for Turdoza
The patent covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease
The money will be used for a Phase IIb clinical trial of its lead programme XF-73
The funding brings equity investment in resTORbio so far this year to US$65mln
Redx said today it has £13.6mln in the bank, which should last it into early 2019
In a £1bn deal, won against five other tenders, Morrison's will supply Safeway products and other national brands to 1,300 McColl's stores and 350 newsagents
British Telecom is developing a habit for unpleasant surprises
Brokers see price parity between electric and non –electric vehicles as early as next year